The Effect Of Menatetrenone, A Vitamin K2 Analog, On Disease Recurrence And Survival In Patients With Hepatocellular Carcinoma After Curative Treatment: A Pilot Study

Effect Decrease
Trial Design Randomized trial
Trial Length 6+ Months
Number of Subjects 61
Sex Both Genders
Age Range 45-64, 65+
Body Types Average, Underweight
Notes for this study:
A pilot study noted that recurrence rates in the group given 45mg MK-4 daily were 12.5% at 12 months, 39.0% at 24 months, and 64.3% at 36 months which significantly outperformed control. The survival rates showed a very strong trend to be improved, but failed to reach statistical significance.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.